Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from candesartan + hydrochlorothiazide to fixed-dose valsartan + hydrochlorothiazide in uncontrolled moderate essential hypertension
2006-001311-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of valsartan + hydrochlorothiazide, candesartan cilexetil and hydrochlorothiazide in essential hypertension, sponsored by Novartis. Primary endpoint: Primary efficacy endpoint. Started Apr 2006; status: completed.
02
Drugs
valsartan + hydrochlorothiazidecandesartan cilexetilhydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2006-001311-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001311-30.